Aytu BioPharma, Inc.
AYTU · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $66,382 | $65,183 | $107,399 | $96,669 |
| % Growth | 1.8% | -39.3% | 11.1% | – |
| Cost of Goods Sold | $20,551 | $16,129 | $40,767 | $46,386 |
| Gross Profit | $45,831 | $49,054 | $66,632 | $50,283 |
| % Margin | 69% | 75.3% | 62% | 52% |
| R&D Expenses | $1,326 | $2,769 | $4,095 | $12,662 |
| G&A Expenses | $17,379 | $19,954 | $28,630 | $31,167 |
| SG&A Expenses | $38,285 | $42,037 | $70,078 | $69,880 |
| Sales & Mktg Exp. | $20,906 | $22,083 | $41,448 | $38,713 |
| Other Operating Expenses | $14,047 | $5,839 | $9,524 | $77,647 |
| Operating Expenses | $53,658 | $50,645 | $83,697 | $160,189 |
| Operating Income | -$7,827 | -$1,591 | -$17,065 | -$109,906 |
| % Margin | -11.8% | -2.4% | -15.9% | -113.7% |
| Other Income/Exp. Net | -$5,918 | -$8,787 | $14 | $1,017 |
| Pre-Tax Income | -$13,745 | -$10,378 | -$17,051 | -$108,889 |
| Tax Expense | $437 | $2,142 | $0 | -$110 |
| Net Income | -$13,562 | -$15,844 | -$17,051 | -$108,779 |
| % Margin | -20.4% | -24.3% | -15.9% | -112.5% |
| EPS | -2.16 | -2.86 | -5.11 | -74.01 |
| % Growth | 24.5% | 44% | 93.1% | – |
| EPS Diluted | -2.16 | -2.86 | -5.11 | -74.01 |
| Weighted Avg Shares Out | 6,280 | 5,538 | 3,340 | 1,470 |
| Weighted Avg Shares Out Dil | 6,280 | 5,538 | 3,340 | 1,470 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $14 |
| Interest Expense | $3,703 | $4,792 | $4,963 | $147,498 |
| Depreciation & Amortization | $5,377 | $6,725 | $8,815 | $10,146 |
| EBITDA | -$4,665 | $1,406 | -$3,273 | -$27,957 |
| % Margin | -7% | 2.2% | -3% | -28.9% |